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Introduction: The anti-fibrotic hormone, relaxin, has been inferred to disrupt
transforming growth factor (TGF)-β1/Smad2 phosphorylation (pSmad2) signal
transduction and promote collagen-degrading gelatinase activity via a nitric oxide (NO)-
dependent pathway. Here, we determined the extent to which NO, soluble guanylate
cyclase (sGC) and cyclic guanosine monophosphate (cGMP) were directly involved in
the anti-fibrotic actions of relaxin using a selective NO scavenger and sGC inhibitor, and
comparing and combining relaxin’s effects with that of an NO donor.
Methods and Results: Primary renal cortical myofibroblasts isolated from injured rat
kidneys were treated with human recombinant relaxin (RLX; 16.8 nM), the NO donor,
diethylamine NONOate (DEA/NO; 0.5–5 µM) or the combined effects of RLX (16.8 nM)
and DEA/NO (5 µM) over 72 h. The effects of RLX (16.8 nM) and DEA/NO (5 µM)
were also evaluated in the presence of the NO scavenger, hydroxocobalamin (HXC;
100 µM) or sGC inhibitor, ODQ (5 µM) over 72 h. Furthermore, the effects of RLX
(30 nM), DEA/NO (5 µM) and RLX (30 nM) + DEA/NO (5 µM) on cGMP levels were
directly measured, in the presence or absence of ODQ (5 µM). Changes in matrix
metalloproteinase (MMP)-2, MMP-9 (cell media), pSmad2 and α-smooth muscle actin
(α-SMA; a measure myofibroblast differentiation) (cell layer) were assessed by gelatin
zymography and Western blotting, respectively. At the highest concentration tested,
both RLX and DEA/NO promoted MMP-2 and MMP-9 levels by 25–33%, while inhibiting
pSmad2 and α-SMA expression by up to 50% (all p < 0.05 vs. untreated and vehicle-
treated cells). However, 5µM of DEA/NO was required to produce the effects seen
with 16.8 nM of RLX over 72 h. The anti-fibrotic effects of RLX or DEA/NO alone were
completely abrogated by HXC and ODQ (both p< 0.01 vs. RLX alone or DEA/NO alone),
but were significantly enhanced when added in combination (all p < 0.05 vs. RLX alone).
Additionally, the direct cGMP-promoting effects of RLX, DEA/NO and RLX DEA/NO+
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(which all increased cGMP levels by 12-16-fold over basal levels; all p< 0.01 vs. vehicle-
treated cells) were significantly inhibited by pre-treatment of ODQ (all p < 0.05 vs. the
respective treatments alone).
Conclusion: These findings confirmed that RLX mediates its TGF-β1-inhibitory and
gelatinase-promoting effects via a NO-sGC-cGMP-dependent pathway, which was
additively augmented by co-administration of DEA/NO.
Keywords: fibrosis, myofibroblasts, cell signaling, relaxin, transforming growth factor-β1, nitric oxide, cGMP
INTRODUCTION
Fibrosis (organ scarring) is a universal manifestation of chronic
or severe tissue injury and represents an aberrant wound healing
response, which in effect results from the failure of the affected
organ to repair and regenerate (Wynn and Ramalingam, 2012).
The pathogenesis of fibrosis in several organs including the
kidney involves consecutive but overlapping events in response
to injury or stress, including inflammation, extracellular matrix
(ECM) synthesis (fibrogenesis) and remodeling (Eddy, 2000;
Hewitson, 2009; Wynn and Ramalingam, 2012). The rate of
ECM synthesis which contributes to fibrosis is dependent
on the activity of various pro-fibrotic cytokines and growth
factors, primarily transforming growth factor (TGF)-β1, and on
myofibroblast burden (Eddy, 2000; Hewitson, 2009; Wynn and
Ramalingam, 2012). Recognized from their de novo expression
of α-smooth muscle actin (α-SMA), myofibroblasts are mainly
derived from the proliferation and differentiation of local
fibroblasts following injury, and synthesize excessive amounts of
collagen and other ECM proteins that form the basis of renal
fibrosis.
In addition to synthesizing ECM components, myofibroblasts
also secrete various ECM degrading proteinases, with the extent
of ECM accumulation depending upon the balance between
ECM synthesis and degradation. The latter can be regulated
by several proteases, of which the matrix metalloproteinase
(MMP) family, that are in turn regulated by tissue inhibitors
of metalloproteinases (TIMPs), are the most studied (Catania
et al., 2007; Hewitson, 2009). The gelatinases, MMP-2 (gelatinase
A) and MMP-9 (gelatinase B) preferentially cleave basement
membrane collagen IV within the kidney, while MMP-2 can also
digest interstitial collagens (Aimes and Quigley, 1995). The effect
of TGF-β1 on gelatinase activity has been demonstrated to be
inhibitory (Howard et al., 2012), but can vary in a time- (Ogawa
et al., 2011) and species/model (Saed et al., 2000; Ogawa et al.,
2011; Ye et al., 2011; Bates et al., 2015)-dependent manner.
The naturally occurring hormone, relaxin, has emerged as
an effective anti-fibrotic in several organs (reviewed in Samuel
and Hewitson, 2006; Bennett, 2009; Du et al., 2014) including
the aged (Samuel et al., 2004b; Danielson et al., 2006) and
injured (Garber et al., 2001, 2003; McDonald et al., 2003; Lekgabe
et al., 2005; Hewitson et al., 2010; Sasser et al., 2011; Yoshida
et al., 2012, 2013) kidney. Relaxin has been well-demonstrated
to inhibit TGF-β1-induced myofibroblast differentiation and
myofibroblast-induced aberrant ECM/collagen production
(Unemori and Amento, 1990; Unemori et al., 1996; Samuel et al.,
2004a; Heeg et al., 2005; Mookerjee et al., 2009), while also being
able to augment ECM/collagen degradation through its ability to
up-regulate various collagenases (Unemori et al., 1996; Bennett
et al., 2003; Kapila et al., 2009; Samuel et al., 2011; Ahmad et al.,
2012; Chow et al., 2012; Bennett et al., 2014) and gelatinases
(Lekgabe et al., 2005; Kapila et al., 2009; Conrad and Shroff, 2011;
Ahmad et al., 2012; Chow et al., 2012; Sassoli et al., 2013; Frati
et al., 2015; Sarwar et al., 2015) and/or inhibit TIMP activity
(Unemori and Amento, 1990; Williams et al., 2001; Samuel et al.,
2008; Sassoli et al., 2013; Bennett et al., 2014).
More recent studies aimed at elucidating the signal
transduction mechanisms by which its TGF-β1-inhibitory
effects are mediated in (myo)fibroblasts have shown that relaxin
signals through its cognate G protein-coupled receptor, relaxin
family peptide receptor 1 (RXFP1), to activate an extracellular
signal-regulated kinase 1/2 phosphorylation (pERK1/2) and
neuronal nitric oxide (NO) synthase (nNOS)-sGC/cyclic
guanosine monophosphate (cGMP)-dependent pathway
(Mookerjee et al., 2009; Chow et al., 2012; Sarwar et al., 2015).
This primarily results in the relaxin-mediated down-regulation
of Smad2 phosphorylation (pSmad2) in several organs (Heeg
et al., 2005; Mookerjee et al., 2009; Bennett et al., 2014; Royce
et al., 2014; Samuel et al., 2014), but also notch-1-induced
down-regulation of pSmad3 in cardiac fibroblasts (Sassoli
et al., 2013). The inhibition of these intracellular proteins, that
promote TGF-β1 signal transduction, leads to suppression of
TGF-β1-induced myofibroblast differentiation and aberrant
ECM/collagen deposition. Furthermore, by down-regulating
TGF-β1 activity at the pSmad2 level, relaxin has been shown to
up-regulate iNOS contributing to its MMP-promoting effects
(Chow et al., 2012).
As many of relaxin’s actions are mediated via NO (Baccari
and Bani, 2008), studies investigating its anti-fibrotic actions
have assumed a role for NO given relaxin’s ability to stimulate
nNOS in cardiac and renal fibroblasts (Mookerjee et al., 2009;
Chow et al., 2012; Sarwar et al., 2015) and/or up-regulate
iNOS in renal and dermal fibroblasts (Chow et al., 2012). This
is supported by reports of an inverse relationship between
NO/cGMP and TGF-β1 (Chu and Prasad, 1999) as well as
pSmad2/pSmad3 (Chen et al., 2011) activity. Moreover, both
NO (Saura et al., 2005) and direct sGC stimulators (Beyer
et al., 2015) have been demonstrated to inhibit TGF-β1 signal
transduction. However, the actual involvement of NO in the
anti-fibrotic actions of relaxin was not directly demonstrated
in those studies. To address this limitation, we investigated the
extent to which NO, sGC and cGMP were directly involved
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in the anti-fibrotic actions of relaxin, by evaluating the effects
of a selective NO scavenger (hydroxocobalamin; HXC) and
sGC inhibitor (ODQ) on four well-known end-points associated
with the anti-fibrotic effects of relaxin: pSmad2, α-SMA (as a
measure of myofibroblast differentiation), MMP-2 and MMP-9.
Furthermore, we compared and combined the effects of relaxin
with a NO donor (diethylamine NONOate; DEA/NO) on these
four end-points, and additionally on cGMP levels, in the absence
or presence of ODQ.
MATERIALS AND METHODS
Cell Culture
Primary renal cortical myofibroblasts were isolated from fibrotic
kidneys of Sprague-Dawley rats 3-days post-ureteric obstruction,
characterized and identified as detailed before (Grimwood and
Masterson, 2009; Mookerjee et al., 2009; Chow et al., 2012),
and used between passages 30–35 (P30–35) for the outlined
studies. Cells were re-characterized at the completion of the
experiments. Based on cytochemical staining for alpha-smooth
muscle actin, 100% of cells were myofibroblasts. Pericytes and
smooth muscle cells were excluded by the absence of positive
staining for the cytoskeletal protein desmin. Isolating cells from
UUO-injured rats was approved by the appropriate Animal
Ethics Committee within the University of Melbourne; which
adheres to the Australian Code of Practice for the care and use
of animals for scientific purposes. It has previously been shown
that cells isolated from fibrotic kidneys are more active and a
better reflection of their in vivo counterparts than fibroblasts
that are cultured from normal kidneys (Rodemann and Muller,
1990). These cells are responsive to recombinant human relaxin
(RLX) treatment as they specifically express RXFP1 (Masterson
et al., 2004; Mookerjee et al., 2009; Chow et al., 2012). Rat
renal myofibroblasts were cultured in Dulbecco’s Modified Eagles
Medium (DMEM; GIBCO-Life Technologies, Grand Island, NY,
USA) containing 10% (v/v) fetal calf serum (FCS; GIBCO-
Life Technologies), penicillin (100 units/mL), streptomycin
(100 µg/mL), 2% (v/v) 1M HEPES (GIBCO-Life Technologies)
and 1% (v/v) 200µM L-glutamine (Sigma–Aldrich, St Louis, MO,
USA) (DMEM-FCS) and were maintained in a 37◦C incubator
with 95% O2/5% CO2. The FCS acted as a protein carrier to
ensure the stability of rhRLX in the culture media, while the renal
fibroblasts were found to grow/proliferate better in the presence
of HEPES and L-glutamine. Cells were cultured to approximately
80–90% confluence before being split and passaged or seeded for
experiments. All experiments described below were performed at
least 3–4 separate times in duplicate.
Determining the Effects of an NO Donor,
NO Scavenger and sGC Inhibitor on the
Anti-fibrotic Effects of RLX
To evaluate the direct contributions of NO and sGC to the
anti-fibrotic effects of RLX, renal myofibroblasts were seeded
in 12-well plates at a density of 1–1.25 × 105 cells/well and
treated with either RLX alone (16.8 nM or 100 ng/ml; which is an
optimal concentration that had previously been shown to inhibit
TGF-β1-induced pSmad2 and α-SMA expression (Masterson
et al., 2004; Mookerjee et al., 2009), while promoting MMP-2
and MMP-9 levels (Chow et al., 2012) in these cells, increasing
concentrations of the NO donor, DEA/NO (0.1, 1, 5 µM; Sigma–
Aldrich) or the combined effects of RLX (16.8 nM) and DEA/NO
(5 µM) for 72 h. DEA/NO was initially made up as a 10 µM
stock solution in 0.01M NaOH (to prevent DEA/NO from
decomposing) and diluted to the appropriate concentrations in
DMEM-FCS immediately prior to addition. DEA/NO was added
three times daily (at ∼5–6 h intervals) over the 72 h treatment-
period, while RLX was added once at the beginning of each
experiment. Untreated cells and cells treated with 10 µM NaOH
(vehicle) alone were used as controls.
In separate experiments, renal myofibroblasts were seeded as
above and treated with DEA/NO (5µM) or RLX (16.8 nM), in the
absence or presence of the NO scavenger, HXC (100 µM; Sigma–
Aldrich; Favaloro and Kemp-Harper, 2007; Andrews et al., 2009)
or sGC inhibitor, ODQ (5 µM; Cayman Chemicals, Ann Arbor,
MI, USA; Mookerjee et al., 2009; Chow et al., 2012) for 72 h. HXC
or ODQ were added once daily over the 72 h treatment-period,
and their effects alone were also evaluated to ensure that they did
not affect basal expression of the various end-points measured.
After 72 h in each case, the media and cell layers were collected
and assayed as described below.
In another set of experiments, renal myofibroblasts were
seeded in 48-well plates at a density of 1 × 105 cells/well and
grown overnight in DMEM-FCS. Cells were serum starved for
6 h before addition of ligands, then pre-treated with or without
ODQ (5 µM) for 15 min prior to stimulation with either
RLX [30 nM; a concentration that had previously been used to
stimulate cGMP levels in fibroblasts (Sarwar et al., 2015)] alone,
DEA/NO (5 µM) alone or the combined effects of RLX (30 nM)
and DEA/NO (5 µM) for 30 min. Myofibroblasts treated with
vehicle (10 µM NaOH) were used to measure basal cGMP levels.
cGMP accumulation was detected using the AlphaLISA cGMP
Detection kit (Perkin Elmer, Hopkington, MA, USA). Cells were
lysed in ice–cold 100% ethanol following addition of 80 µL
of lysis buffer. Twenty microliter lysate was transferred to the
384-well optiplate (PerkinElmer) and analyzed according to the
manufacturer’s instructions.
Protein Isolation and Western Blotting
After the media was removed, the cells within each well
were washed with Dulbecco’s Phosphate-Buffered Saline (DPBS)
(GIBCO-Life Technologies) to remove any residual media. After
discarding the DPBS, cells were then treated with Accutase
solution (Sigma–Aldrich, St Louis, MO, USA) and incubated at
37◦C for 5 min to facilitate the harvest of cells from the 12-well
plates. Harvested cells were then transferred to Eppendorf tubes
and centrifuged at 7000 rpm for 10 min. Cell pellets from each
well were then re-suspended in 20 µL of RIPA lysis buffer and
incubated on ice for at least 30 min for cell lysis. After incubation,
the cell lysates were centrifuged at 13200 rpm for 10 min at 4◦C,
thereafter the supernatants were collected and transferred to new
Eppendorf tubes and stored at−80◦C until required.
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Equivalent one-third portions of each protein sample (for
the analysis of pSmad2, total Smad2/3 and α-SMA) were
separated on pre-cast 10% SDS-polyacrylamide separating
gels (Bio-Rad, Philadelphia, PA, USA) as described before
(Chow et al., 2012), and transferred to PVDF membranes
using the Bio-Rad Trans-Blot Turbo transfer system (Bio-
Rad, Philadelphia, PA, USA), before membranes were blocked
for 1 h with 5% (w/v) skim milk powder. Membranes were
then probed with primary rabbit monoclonal antibodies to
either total Smad2/3 (#3102; 1:1000 dilution; Cell signaling,
Danvers, MA, USA) or pSmad2 (#3108; 1:1000 dilution; Cell
signaling), or with a primary mouse monoclonal antibody to
α-SMA (M0851; 1:1000 dilution; DAKO, Glostrup, Denmark)
for at least 16 h at 4◦C. Membranes were then probed
with a goat anti-rabbit antibody (1:2500 dilution; DAKO) to
detect total Smad2/3 and pSmad2; while a goat anti-mouse
antibody (1:2000 dilution; DAKO) was used to detect α-SMA.
Membranes were then developed with the Bio-Rad Clarity
Western ECL substrate kit (Bio-Rad) for 5 min according
to the manufacturer’s protocol followed by visualization and
imaging using the Bio-rad ChemicDoc MP. The optical density
(OD) of the appropriate bands were then quantified and
analyzed using Image Lab software (Bio-Rad). The measured
density of pSmad2 and α-SMA were then corrected to the
density of total Smad2/3, expressed as the relative ratio to that
measured from the untreated or vehicle-treated control group
(which was expressed as 1 in each case), and subsequently
presented as the mean OD for pSmad2 or α-SMA from
the n = 3–4 separate experiments performed per treatment
group.
Gelatin Zymography
Changes in latent (L) and active (A) MMP-2 and MMP-
9 levels that were secreted from rat renal myofibroblasts
into the cell media over the 72 h experimental period,
were assessed by gelatin zymography as described previously
(Chow et al., 2012). Equal volumes of each sample were
electrophoresed on 7.5% acrylamide gels containing 1mg/ml
gelatin. Gelatinolytic activity was indicated by clear bands
and densitometry of these MMP bands was performed using
the Bio-rad ChemicDoc MP and Image Lab software (Bio-
Rad). The mean ± SEM of each (combined latent and active)
MMP was then determined and expressed as the relative
ratio to that measured from the untreated or vehicle-treated
control group (which was expressed as 1 in each case); from
the n = 3–4 separate experiments performed per treatment
group.
Statistical Analysis
All statistical analyses was performed using GraphPad
Prism v6.0 (GraphPad Software Inc., La Jolla, CA,
USA). All data were expressed as the mean ± SEM and
analyzed by one-way ANOVA, using a Neuman–Keuls
post hoc test to allow for multiple comparisons between
groups; while differences in cGMP levels were analyzed
by Student’s t-tests. P < 0.05 was considered statistically
significant.
RESULTS
The Individual vs. Combined Effects of
RLX and DEA/NO on Measures of Renal
Fibrosis
The effects of RLX (16.8 nM) on renal pSmad2, α-SMA
expression, MMP-2 and MMP-9 levels were firstly compared to
increasing concentrations of DEA/NO (0.1–5 µM) (Figure 1);
and then combined with the highest concentration of DEA/NO
evaluated (5 µM) (Figure 2). As previously demonstrated
(Masterson et al., 2004; Mookerjee et al., 2009; Chow et al.,
2012), RLX (16.8 nM) significantly inhibited pSmad2 and α-SMA
expression by 35–50% (Figures 1A and 2A), but increased
both MMP-2 and MMP-9 levels by 25–30% (Figures 1B
and 2B) over 72 h in culture (all P < 0.05 vs. untreated
control group). Although the magnitude of some of these
RLX-induced effects were not as great as that reported
previously (Masterson et al., 2004; Mookerjee et al., 2009;
Chow et al., 2012), this may be due to the heterogeneity of
primary cell cultures. In comparison, DEA/NO was found to
concentration-dependently inhibit renal pSmad2 levels by∼10%,
∼30% and ∼33% when administered at 0.1, 1, and 5 µM,
respectively, over 72 h in culture (all P < 0.05 vs. vehicle-
treated group; Figure 1A). Likewise, DEA/NO significantly
inhibited α-SMA expression by ∼40 and ∼60% at 1 and 5 µM,
respectively, over the same time period (both P < 0.01 vs.
untreated control and vehicle-treated groups; Figure 1A). On
the other hand, the NO donor significantly increased MMP-
2 and MMP-9 levels by ∼33 and ∼25%, respectively (both
P < 0.05 vs. untreated control and vehicle-treated group),
but only when administered at a concentration of 5 µM
(Figure 1B).
Combining RLX (16.8 nM) with DEA/NO (5 µM) resulted in
a further additive reduction of pSmad2 and α-SMA expression
over 72 h in culture, by 50–55% over the effects of RLX alone
(both P < 0.001 vs. vehicle-treated group; P < 0.01 vs. RLX
alone-treated group; Figure 2A). Similarly, combining RLX and
DEA/NO additively promoted both MMP-2 and MMP-9 levels
over 72 h, by ∼15% over the effects of RLX alone or DEA alone
(both P < 0.001 vs. vehicle-treated group; P < 0.05 vs. RLX
alone-treated group; P < 0.05 vs. DEA/NO alone-treated group;
Figure 2B).
The Effects of HXC and ODQ on the
Anti-fibrotic Effects of DEA/NO and RLX
To further verify whether the effects of RLX were mediated via
NO and sGC, its anti-fibrotic effects were next evaluated in the
absence or presence of the NO scavenger, HXC (100 µM) and
sGC inhibitor, ODQ (5 µM). The specificity of the effects of
HXC and ODQ was first established in studies demonstrating that
they were also able to completely abrogate the DEA/NO (5 µM)-
induced down-regulation of pSmad2 and α-SMA expression
(Figure 3A) in addition to the DEA/NO-mediated promotion
of gelatinase expression (Figure 3B) (all P < 0.01 vs. DEA/NO
alone-treated group), without affecting basal expression of these
end-points over 72 h in culture.
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FIGURE 1 | The effects of RLX vs. DEA/NO on pSmad2, α-SMA, MMP-2 and MMP-9. Shown are (A) representative (duplicate samples from one experiment)
Western blots of pSmad2 and α-SMA; and (B) gelatin zymographs of latent (L) and active (A) MMP-2 and MMP-9 from untreated control rat renal myofibroblasts and
cells treated with vehicle (10 µM NaOH) alone, RLX (16.8 nM) alone or increasing concentrations of DEA/NO (0.1–5 µM) alone, after 72 h in culture. Also shown are
the mean ± SEM optical density (OD) of (A) pSmad2 and α-SMA (corrected for Smad2/3 loading); and (B) (latent and active) MMP-2 and MMP-9, as determined
from densitometry measurements of the Western blots or zymographs. Numbers in parenthesis represent the number of independent experiments carried out in
duplicate. ∗P < 0.05, ∗∗P < 0.01 vs. respective groups highlighted.
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FIGURE 2 | The combined effects of RLX and DEA/NO on pSmad2, α-SMA, MMP-2 and MMP-9. Shown are (A) representative (duplicate samples from one
experiment) Western blots of pSmad2 and α-SMA; and (B) gelatin zymographs of latent (L) and active (A) MMP-2 and MMP-9 from vehicle (10 µM NaOH)-treated
rat renal myofibroblasts and cells treated with RLX (16.8 nM) alone, DEA/NO (5 µM) alone or the combined effects of RLX (16.8 nM) alone and DEA/NO (5 µM) after
72 h in culture. Also shown are the mean ± SEM OD of (A) pSmad2 and α-SMA (corrected for Smad2/3 loading); and (B) (latent and active) MMP-2 and MMP-9, as
determined from densitometry measurements of the Western blots or zymographs. Numbers in parenthesis represent the number of independent experiments
carried out in duplicate. ∗∗P < 0.01, ∗∗∗P < 0.001 vs. respective groups highlighted.
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FIGURE 3 | The effects of HXC and ODQ on basal and DEA/NO-mediated changes of pSmad2, α-SMA, MMP-2 and MMP-9. Shown are (A)
representative (duplicate samples from one experiment) Western blots of pSmad2 and α-SMA; and (B) gelatin zymographs of latent (L) MMP-2 and MMP-9 from
vehicle (10 µM NaOH)-treated rat renal myofibroblasts and cells treated with HXC (100 µM), ODQ (5 µM) alone, DEA/NO (5 µM) alone or the combined effects of
DEA/NO (5 µM) and HXC (100 µM) or ODQ (5 µM), after 72 h in culture. Also shown are the mean ± SEM optical density (OD) of (A) pSmad2 and α-SMA (corrected
for Smad2/3 loading); and (B) (latent) MMP-2 and MMP-9, as determined from densitometry measurements of the Western blots or zymographs. Numbers in
parenthesis represent the number of independent experiments carried out in duplicate. ∗∗P < 0.01 vs. respective groups highlighted.
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FIGURE 4 | The effects of HXC and ODQ on RLX-mediated changes of pSmad2, α-SMA, MMP-2 and MMP-9. Shown are (A) representative (duplicate
samples from one experiment) Western blots of pSmad2 and α-SMA; and (B) gelatin zymographs of latent (L) MMP-2 and MMP-9 from untreated (control) rat renal
myofibroblasts and cells treated with RLX (16.8 nM) alone or the combined effects of RLX (16.8 nM) and HXC (100 µM) or ODQ (5 µM), after 72 h in culture. Also
shown are the mean ± SEM optical density (OD) of (A) pSmad2 and α-SMA (corrected for Smad2/3 loading); and (B) (latent) MMP-2 and MMP-9, as determined
from densitometry measurements of the Western blots or zymographs. Numbers in parenthesis represent the number of independent experiments carried out in
duplicate. ∗∗P < 0.01 vs. respective groups highlighted.
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Similarly, the ability of RLX (16.8 nM) to down-regulate
pSmad2 and α-SMA expression was completely abrogated by
either co-administration of the NO scavenger, HXC (100 µM) or
the sGC inhibitor, ODQ (5 µM) (both P < 0.05 vs. RLX alone-
treated group; Figure 4A) over 72 h. Likewise, the ability of RLX
to promote MMP-2 and MMP-9 levels was completely abrogated
by co-administration of HXC or ODQ over the same time period
(both P < 0.01 vs. RLX alone-treated group; Figure 4B).
The Effects of ODQ on the
cGMP-Promoting Effects of RLX and
DEA/NO
To further confirm that RLX was mediating its effects via cGMP,
which is typically stimulated by sGC upon NO activation, direct
measurement of cGMP accumulation from renal myofibroblasts
was found to be strikingly increased by RLX (30 nM) or DEA/NO
(5 µM) alone (by 12–13-fold; both P < 0.01 vs. basal (vehicle-
treated) cGMP levels; Figure 5). Combining RLX and DEA/NO
tended to increase cGMP levels further (by 16-fold), although
this change was not statistically significant as compared to either
treatment alone (Figure 5). These cGMP-promoting effects of
RLX, DEA/NO or the combined effects of both were significantly
inhibited by pre-administration of ODQ (5 µM) (all P < 0.05 vs.
respective treatments alone; Figure 5).
DISCUSSION
This study aimed to further elucidate and confirm the molecular
mechanisms by which the anti-fibrotic hormone, relaxin,
inhibited the TGF-β1/pSmad2 axis (Heeg et al., 2005; Mookerjee
et al., 2009). As the effects of RLX were enhanced in the
presence of an NO donor, but abrogated in the presence of
an NO scavenger, to the best of our knowledge, this study has
demonstrated for the first time a direct contribution of NO to
the TGF-β1-inhibitory effects of RLX. Furthermore, for the first
time, we have shown that RLX directly stimulates cGMP upon
its administration to rat renal myofibroblasts. Previous studies
have shown that RLX up-regulates nNOS expression (of the
NOS isoforms) in RXFP1-expressing rat renal myofibroblasts
(Masterson et al., 2004; Mookerjee et al., 2009; Chow et al.,
2012) and human cardiac fibroblasts (Sarwar et al., 2015). In this
context, our findings have confirmed that relaxin signals through
a RXFP1-pERK1/2-nNOS-NO-sGC-cGMP-dependent pathway
to mediate its anti-fibrotic actions. Additionally, this study
provided the first evidence that the NO donor, DEA/NO, could
also induce anti-fibrotic actions via a sGC-cGMP-dependent
pathway, leading to inhibition of TGF-β1 signal transduction
(at the level of pSmad2) and subsequently, the pro-fibrotic
influence of TGF-β1 on renal myofibroblast differentiation, while
being able to promote collagen-degrading gelatinases (MMP-2
and MMP-9). Importantly, from a therapeutic perspective, our
findings strongly suggest that combining RLX with NO donors
would enhance its anti-fibrotic efficacy.
The TGF-β1-inhibitory effects of RLX have been well-
documented in various (myo)fibroblast culture models in vitro
(Unemori and Amento, 1990; Unemori et al., 1996; Samuel et al.,
FIGURE 5 | The effects of ODQ on RLX ± DEA/NO-mediated changes
in cGMP accumulation. Shown are the mean ± SEM cGMP levels in rat
renal myofibroblasts treated for 30 min with RLX (30 nM), DEA/NO (5 µM), or
the combined effects of both; and sub-groups of correspondingly treated cells
that were pre-exposed to ODQ (5 µM) for 15 min prior to administration of
RLX + DEA/NO. Numbers in parenthesis represent the number of
independent experiments carried out. ∗P < 0.05, ∗∗P < 0.01 vs. respective
groups highlighted.
2004a; Heeg et al., 2005) and animal models of disease in vivo
(Garber et al., 2001; Mookerjee et al., 2009; Samuel et al., 2011,
2014; Bennett et al., 2014). As detailed in Section “Introduction,”
RLX binding and activation of its cognate receptor, RXFP1, on
renal myofibroblasts results in the phosphorylation of ERK1/2
and activation of nNOS to inhibit pSmad2 (Mookerjee et al.,
2009; Chow et al., 2012), in the absence of any direct effects on
Smad3, Smad4, or Smad7 (Heeg et al., 2005), to disrupt TGF-
β1 signal transduction. The findings from this study also support
previous reports (Mookerjee et al., 2009; Chow et al., 2012) in
demonstrating that the selective sGC inhibitor, ODQ (at 5 µM)
was able to abolish the RLX-mediated inhibition of pSmad2 and
α-SMA expression, in addition to its ability to promote gelatinase
levels in the rat renal myofibroblasts studied. For the first time,
they now demonstrate that the cGMP-promoting effects of RLX
in these cells are also inhibited by ODQ. Based on previous
studies in endothelial cells, it is likely that in renal myofibroblasts
cGMP generated by stimulation of sGC suppresses Smad2/3
phosphorylation via a cGMP-dependent protein kinase 1 (PKG-
1)-dependent manner (Saura et al., 2005). However, this is yet
to be confirmed. Subsequently, inhibition of TGF-β1 releases
various MMPs including MMP-2 and MMP-9 via an iNOS-
dependent mechanism (Chow et al., 2012), which collectively
contributes to the anti-fibrotic actions of RLX.
The therapeutic potential of targeting the NO-sGC-cGMP
signaling pathway in kidney fibrosis was further highlighted by
our findings with the NO donor, DEA/NO. DEA/NO, which
spontaneously decomposes to generate NO with a half-life of
∼2.5 min, exhibited similar anti-fibrotic actions to that of
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RLX (but at relatively higher concentration), which were
sensitive to HXC and ODQ and thus, mediated via
the NO-sGC-cGMP signaling pathway. These findings
are supported by several in vivo and in vitro studies
which have indicated that other NO donors can reduce
fibrosis in multiple organs. For example, the NO donors
molsidomine and sodium nitroprusside (SNP) were found
to protect against liver fibrosis in rodents (Ozturk et al.,
2002; Ali et al., 2012), while SNP and diethylenetetra-
amine NONOate (DETA/NO) were reported to modulate
human lung fibroblast proliferation (Liu et al., 2001).
In myofibroblast culture models, it has also been
reported that exogenous NO, donated by S-nitroso-N-
acetyl penicillamine (SNAP), could inhibit myofibroblast
proliferation, differentiation and collagen production (Vernet
et al., 2002). In accordance with the current findings, these
studies attributed the anti-fibrotic actions of NO donors to
inhibition of the TGF-β1/Smad2 axis (Saura et al., 2005),
suggesting a potential common mode of action of NO in
myofibroblasts.
In contrast, other studies have demonstrated that the
exogenous NO donor, DETA/NO (125–500 µM; t1/2 ∼20 h),
promoted TIMP-1, TGF-β1 and collagen synthesis in fibrosis-
related disorders such as keloid (hypertrophic scar) and
pulmonary fibrosis (Hsu et al., 2007). Moreover, while others
have reported MMP-inhibitory effects of DETA/NO (500 µM)
in a vascular model (Gurjar et al., 1999), our study suggested
that DEA/NO (5 µM; t1/2 ∼2.5 min) was able to promote
MMP-2 and MMP-9 levels in myofibroblasts (which lack eNOS
Mookerjee et al., 2009). These different findings with respect
to the impact of NO donors on measures of fibrosis may
reflect the use of NO donors with varying half-lives and at
different concentrations, modulation of distinct downstream
targets of cGMP and the study of diverse disease etiologies.
Although further work is required to investigate which NO
donors mediate the most efficacious anti-fibrotic effects in
various pathological scenarios, our study demonstrates that
DEA/NO at least exerts its anti-fibrotic actions through a
similar mode of action to that of RLX, and in fact additively
potentiates the anti-fibrotic effects of RLX. Collectively our
data highlights the therapeutic potential of targeting the NO-
sGC-cGMP signalling pathway in the treatment of fibrosis.
In view of this, it would of great interest to evaluate the
combined anti-fibrotic effects of RLX with the new generation
NO-independent sGC stimulators (BAY 41-2272; Beyer et al.,
2015) and/or cGMP analogs (8-Br-cGMP; Rivero-Vilches et al.,
2003), the former demonstrating excellent safety and tolerability
in phase III trials in patients with pulmonary hypertension.
In particular, greater synergy may be achieved between RLX
and BAY 41-2272, which target canonical and non-cononical
(Beyer et al., 2015) TGF-β1 signal transduction pathways,
respectively.
Despite the positive implications of these findings, there
were a number of limitations with this study that need
to be addressed in future investigations to further validate
and translate the therapeutic potential of the treatments that
were investigated. Firstly, the end-points measured were all
completed from a cell culture model; albeit from cells isolated
from injured rat kidneys (which are more reflective of their
in vivo counterparts). Having said that, the findings obtained
were consistent with data obtained from TGF-β1-stimulated
human renal fibroblast cell lines (Heeg et al., 2005) and
RLX-treated mice in vivo (Chow et al., 2014). Secondly, only
one NO donor and one NO scavenger were used. However,
our findings that HXC and ODQ were able to negate the
effects of both the NO donor, DEA/NO and RLX strongly
suggests that the effects of RLX were mediated via a NO-sGC-
dependent mechanism. Given that NO scavengers and sGC
inhibitors cannot be administered to the intact animal, they
cannot be used to delineate the contribution of the NO-sGC-
cGMP signaling pathway to the anti-fibrotic actions of RLX
in vivo. Finally, while NO and sGC levels were not directly
determined, we were able to demonstrate that the RLX- and
DEA/NO-induced increase in cGMP accumulation was blocked
by ODQ, confirming that RLX was able to signal through a NO-
sGC-cGMP-dependent mechanism to mediate its anti-fibrotic
actions in vitro.
Despite these limitations, this study confirmed at least
at the in vitro level, that RLX mediates its overall anti-
fibrotic actions in primary renal myofibroblasts via a NO-
sGC-cGMP-dependent mechanism. As RLX is currently being
assessed in phase III clinical trials for its cardio-protective
and vasodilatory properties (Teerlink et al., 2013) and NO
donors have been evaluated for their ability to treat fibrosis
(Ozturk et al., 2002; Vernet et al., 2002; Ali et al., 2012),
there is tremendous potential for combining these therapies
to achieve added organ protection and reduced mortality.
Extending this combination approach to the in vivo level will
be key to translating the findings demonstrated in the current
study.
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